HAIFA, Israel, August 17, 2026, Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its majority-owned food-tech portfolio company, Ever After Foods Ltd. (EAF), an industrial technology company developing an open manufacturing platform for cultivated-protein, has acquired Fishway BV, a Belgium-based biotechnology company specializing in aquatic cell biology and animal-component-free (ACF) media development.
EAF provides an open manufacturing platform for the cultivated-protein industry, integrating biology, media, bioprocess engineering and advanced manufacturing. The acquisition adds Fishway’s know-how and related scientific capabilities and expertise in aquatic cell biology and ACF media development to EAF’s bioprocess and manufacturing platform and supports EAF’s strategy to expand its capabilities with a broader range of cultivated-protein applications. Fishway also gives EAF an established scientific presence in Belgium, expanding its European footprint and adding specialized capabilities to its platform, thus strengthening EAF’s ability to work with food and ingredient companies as they move from development toward scalable production.
In parallel with the transaction, EAF should secure an additional $2 million strategic investment through a simple agreement for future equity (“SAFE Agreement”) being entered into in connection with the acquisition of Fishway, to support ongoing platform development and commercialization activities.
“The next phase of the cultivated protein industry will increasingly depend on integrating complementary technologies into scalable industrial platforms. Fishway adds strong capabilities in aquatic cell biology and animal-component-free media that complement Ever After Foods’ production platform and expand the range of applications we can support. This is an important first step in executing our broader platform strategy,” said Eyal Rosenthal, CEO of Ever After Foods.
“Ever After Foods shows how Pluri’s cell-based technology and manufacturing experience can create value and be applied to practical solutions for the food industry,” said Yaky Yanay, President and Chief Executive Officer of Pluri. “Fishway brings complementary science, talent and a European base to EAF. We believe this is a focused strategic step that strengthens the platform and EAF’s ability to support customers as they move toward commercial-scale cultivated protein production.”
Ever After Foods is an industrial technology company building the next generation of protein manufacturing infrastructure. Its open, species-agnostic platform integrates biology, media, bioprocess engineering and advanced manufacturing technologies into scalable production systems that enable food and ingredient companies to produce next-generation proteins efficiently, sustainably and at industrial scale.
Fishway is a Belgium-based cell-biology developer, specializing in aquatic cell lines and animal-component-free (ACF) media for the cultivated-protein industry.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. Pluri’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges, from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri currently operates in the regenerative medicine, longevity, foodtech and agtech fields and offers Contract Development and Manufacturing Organization (CDMO) services. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the additional capabilities of EAF’s platform following the acquisition; the closing of the transaction; the potential benefits of the transaction, the potential to receive an additional $2 million investment through a SAFE Agreement; EAF’s European footprint expansion; that Pluri’s technology and experience will create value and will be applied to practical solutions for the food industry; and that EAF’s ability to support customers as they move toward commercial-scale cultivated protein production will strengthen. These forward-looking statements are based on the current expectations of management only and are subject to factors and uncertainties that could cause actual results to differ materially, including: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a market with an estimated size of ~$900 million annually, and strengthens the foundation for broader international expansion
HAIFA, Israel, July 28, 2026, Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. (“Cellav”), has successfully completed the cosmetic regulatory registration and notification process in the UK, supporting a coming commercial launch of its regenerative aesthetics product, Regenativo+, marking another significant milestone in the Company’s commercialization strategy.
The regulatory registration enables Cellav to commercially market its product in the UK and represents an important step in the Company’s broader strategy to establish a global presence in the fast-growing regenerative aesthetics and longevity markets.
The product has been successfully notified on the UK Cosmetic Product Notification (UKCP) portal. This UK registration complements Cellav’s recent U.S. regulatory progress and expands the Company’s commercial footprint into one of Europe’s leading medical aesthetics markets. With the UK market size estimated at approximately $900 million in 2026 and the European market exceeding $7.5 billion in 2025, we believe that the regulatory registration represents a significant step in Cellav’s strategy to bring regenerative and cell-derived aesthetic products to a growing customer base that is seeking advanced, science-driven solutions.
The registered product, Regenativo+, a plant-derived treatment, is designed for professional aesthetic use and is based on Cellav’s science-driven approach to regenerative aesthetics, leveraging advanced bioactive ingredients and formulations developed through Pluri’s extensive expertise in cell biology and scalable manufacturing.
Cellav’s aesthetic platform is part of Pluri’s broader strategy to expand beyond traditional therapeutic applications and create new value-generating opportunities based on the Company’s proprietary cell-expansion technologies and two decades of expertise in cell-derived products.
“We believe that completing the regulatory registration process in the UK represents another important commercial milestone for Cellav and further validates our strategy of translating decades of regenerative science into market-ready products,” said Yaky Yanay, President and Chief Executive Officer of Pluri. “Following our recent regulatory achievements in the United States, we continue to build the foundation for a global commercial business, focused on regenerative aesthetics, longevity, and wellness.”
“Cellav is actively advancing commercial discussions with aesthetic clinics, distributors, and strategic partners in the UK while continuing to pursue additional regulatory registrations and commercial opportunities in other international markets. Our goal is to make evidence-based regenerative technologies more accessible to aesthetic professionals and consumers seeking innovative solutions,” said Katty Dowery, Chief Executive Officer of Cellav.
Cellav is a biotechnology-driven health and aesthetics company focused on developing next-generation regenerative aesthetics, longevity and skin-health solutions. The Company, built on Pluri’s proprietary 3D cell-expansion platform combines advanced cell-based science clinically driven development and scalable manufacturing capabilities to create innovative products and bioactive platforms for the global aesthetics market.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges, from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri currently operates in the regenerative medicine, longevity, foodtech and agtech fields and offers Contract Development and Manufacturing Organization (CDMO) services. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses a commercial launch of regenerative aesthetics portfolio in the UK market; the size and other projections related to the UK market; any milestones, steps and achievements in its commercialization strategy and broader strategy in general; marketing of Cellav’s products in the UK market; its global presence; growth of regenerative aesthetics and longevity markets; expansion of its commercial footprints; Cellav’s ability to leverage advanced bioactive ingredients and formulations developed through Pluri’s extensive expertise in cell biology and scalable manufacturing; the ability to expand beyond traditional therapeutic applications and create new value-generating opportunities; its ability to translate regenerative science into market-ready products, its ability to build a commercial business focused on regenerative aesthetics, longevity, and wellness; any commercial discussions with partners in the UK; its ability to pursue additional regulatory registrations and commercial opportunities in other international markets; and Cellav’s ability to make evidence-based regenerative technologies more accessible to aesthetic professionals and consumers. These forward-looking statements are based on the current expectations of management only and are subject to factors and uncertainties that could cause actual results to differ materially, including: cosmetic products are not intended to diagnose, treat, cure or prevent any disease, and clinical data referenced herein were generated to support cosmetic-claim substantiation, not any therapeutic indication; results from in-vitro studies and limited-population clinical evaluations may not be predictive of broader real-world results; the Company may not realize anticipated commercial benefits from the UK. listing; Cellav may not successfully commercialize the products on the timeline expected, or at all; market-size estimates, growth projections and statements regarding investor capital flows are based on third-party sources Pluri has not independently verified; competition; the Company’s ability to obtain additional capital; intellectual property risks; and general market, economic and geopolitical conditions. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
investor.relations@pluri-biotech.com
HAIFA, Israel, July 14, 2026 – Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided an update on the cumulative investment and ownership position of its Chairman, Mr. Alejandro Weinstein. Over the past year, Mr. Weinstein has invested more than $17 million in Pluri through a series of investments, including a $1.25 million advance investment made in June 2026 pursuant to an Advance Subscription Agreement, as disclosed in the Company’s Form 8-K filed on June 22, 2026. Mr. Weinstein currently owns more than 30% of the Company’s issued and outstanding shares. His growing commitment comes as Pluri advances its transition from platform development toward commercial execution, with an increasing focus on longevity and planned commercial activity in the United States. Alongside this strategic progress, Pluri is seeing strong inbound interest from multiple U.S. parties exploring potential product purchases and technology collaborations based on the Company’s capabilities in reproducible cell production, tailored exosomes and other unique biological components.
Mr. Weinstein is a global investor and entrepreneur with more than two decades of experience across pharmaceuticals, biotechnology and wellness. As previously reported by Pluri, he has participated in more than 20 M&A transactions and over $5 billion in exits, including transforming CFR Pharmaceuticals into a multinational group acquired by Abbott for approximately $2.9 billion. He began building his position in Pluri after identifying its proprietary 3D cell-expansion platform as a differentiated technology with broad potential and became Chairman of the Board in December 2025.
His interest in the company is based on Pluri’s ability to translate its scientific and technological capabilities into commercial opportunities. As Chairman, Mr. Weinstein has supported a strategic focus on commercialization, disciplined resource allocation and execution across the Company’s platform and business verticals. Pluri is now advancing commercial initiatives in the United States and other markets, reflecting its broader transition from platform development toward commercial operations.
“My commitment to Pluri is reflected in the position I have built over the past year and is based on a clear belief in the Company’s platform, people and assets,” said Alejandro Weinstein, Chairman of the Board of Pluri. “I am convinced that Pluri’s platform holds significant and still largely untapped value, particularly as the Company expands its focus in the rapidly growing longevity sector. The impact of peptide-based medicines, including GLP-1-based therapies developed by Eli Lilly and Novo Nordisk, highlights the strategic value of precision biologics. Pluri can already produce tailored exosomes with distinct biological cargo profiles. We believe this capability could support a future generation of biologic products and attract interest from strategic investors and pharmaceutical companies. Together with reproducible cell production at scale, this creates a differentiated foundation for commercialization. Pluri’s shift toward commercial execution in the U.S. market, with a focus on longevity, tailored biologics and regenerative solutions, is exactly the direction I believe in. I am committed to seeing this strategy through and helping unlock the full potential of the Company for its shareholders.”
“Alejandro’s cumulative investment is a strong expression of confidence in Pluri’s strategy and long-term potential,” said Yaky Yanay, President and Chief Executive Officer of Pluri. “As Chairman and one of our largest shareholders, Alejandro has been actively involved in sharpening our commercial focus and supporting our transition toward market execution. We are seeing strong inbound interest from multiple U.S. parties interested in potential product purchases and technology collaborations built around our capabilities in reproducible cell production, tailored exosomes and unique biological components. His additional investment made in June further reinforces that long-term commitment as we move from platform development toward commercial execution.”
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges, from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri currently operates in the regenerative medicine, regenerative aesthetics, exosomes, longevity, foodtech and agtech fields and offers Contract Development and Manufacturing Organization (CDMO) services. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, Pluri is using forward-looking statements when it discusses its commercial expansion in the United States; opportunities in longevity, tailored biologics and exosomes; its ability to produce tailored exosomes with distinct biological cargo profiles; the potential of such exosomes to support future biologic products; expected interest from strategic investors, pharmaceutical companies and other partners; and Pluri’s strategy, long-term potential and unlocking potential for shareholders. These statements are based on management’s current expectations and are subject to risks and uncertainties, including the Company’s ability to execute its commercialization strategy, develop and manufacture tailored exosome products, secure orders and collaborations, satisfy regulatory requirements, protect intellectual property, obtain capital and compete successfully, as well as general market, economic and geopolitical conditions. References to Eli Lilly and Novo Nordisk are for market context only and do not imply any relationship or endorsement. Except as required by law, Pluri undertakes no obligation to update these statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
investor.relations@pluri-biotech.com
Two regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030
HAIFA, Israel, June 2, 2026, Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. (“Cellav”), has completed the development and U.S. cosmetic product listings of two flagship regenerative aesthetic products – Regenativo+ and Placento+, clearing the path for commercial launch in the United States.
With the U.S. commercial launch and its professional portfolio now listed under the U.S. cosmetic framework and pursuant to U.S. Food and Drug Administration (FDA) regulation, Cellav is in active discussions with U.S. distributors, clinic networks and advancing commercial discussions with strategic partners across the United States, United Kingdom and additional international markets. The Company is focused on securing initial commercial orders, expanding adoption among licensed aesthetic professionals and building a scalable commercial platform for future growth.
The products, Regenativo+, a plant-derived treatment, and Placento+, a placenta-derived formulation, are supplied in Cellav’s signature DUO format: a vial of lyophilized powder paired with a booster vial, designed for topical, professional use following aesthetic procedures.
Clinical validation of Cellav’s ingredients underscores commercial readiness: statistically significant improvements (p<0.05) in skin distensibility, elasticity, firmness and the skin-fatigue index, using plant-based extra cellular vesicles (EV) ingredients. Another study using placenta-based secretome and exosomes, demonstrated significant improvements (p<0.05) in vascular tone (redness) and brown discoloration, with additional improvements in pigmented spots observed in subjects with higher baseline values, and favorable trend observed in skin texture. The tested ingredients were well tolerated, with no clinically meaningful adverse events reported, supporting Cellav’s premium positioning in the professional regenerative and longevity channel.
“We believe that Pluri has built the most advanced cell-expansion platforms in the industry. Today, that technology moves from the lab to the market,” said Yaky Yanay, President and Chief Executive Officer of Pluri. “Our first U.S. commercial launch through Cellav opens access to one of the fastest-growing and highest-margin segments in consumer health. With a clinically validated, scalable portfolio in hand, we believe that we are positioned to capture meaningful share and translate our technology leadership into shareholder value. It also deepens Pluri’s foothold in the longevity field, one of the most strategically important and capital-attractive frontiers in biotech today, where we believe that our proprietary cell-expansion platform is uniquely positioned to lead.”
“This milestone represents the transition of Cellav from product development to commercialization,” said Katty Dowery, Chief Executive Officer of Cellav. “Over the past several years, we have focused on building the scientific, manufacturing, clinical and regulatory foundations required to enter the aesthetics market responsibly and at scale. With our first professional products now listed in the U.S., we are focused on establishing strategic partnerships, building a meaningful commercial presence, and expanding our pipeline of next-generation regenerative aesthetics solutions.”
Cellav is a biotechnology-driven health and aesthetics company focused on developing next-generation regenerative aesthetics, longevity and skin-health solutions. The Company, built on Pluri’s proprietary 3D cell-expansion platform combines advanced cell-based science clinically driven development and scalable manufacturing capabilities to create innovative products and bioactive platforms for the global aesthetics market.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges, from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri currently operates in the regenerative medicine, longevity, foodtech and agtech fields and offers Contract Development and Manufacturing Organization (CDMO) services. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses that the U.S. cosmetic product listing of Regenativo+ and Placento+ supports its U.S. commercial market entry and establishes near-term commercial opportunities for it in the rapidly growing regenerative aesthetics sector, that Cellav is in active discussions with U.S. distributors, clinic networks and advancing commercial discussions with strategic partners, that it is focused on securing initial commercial orders, expanding adoption among licensed aesthetic professionals and building a scalable commercial platform for future growth, that the tested ingredients of its product were well tolerated, with no clinically meaningful adverse events reported, which supports Cellav’s premium positioning in the professional regenerative and longevity channel, the belief that Pluri has built the most advanced cell-expansion platforms in the industry, that with a clinically validated, scalable portfolio in hand, it believes that it is positioned to capture meaningful share and translate its technology leadership into shareholder value, its belief that its proprietary cell-expansion platform is uniquely positioned to lead, and Pluri’s growth strategy. These forward-looking statements are based on the current expectations of management only and are subject to factors and uncertainties that could cause actual results to differ materially, including: U.S. cosmetic product listing does not constitute FDA approval, and listed products remain subject to ongoing regulatory requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), including post-market surveillance, adverse-event reporting and labeling compliance; cosmetic products are not intended to diagnose, treat, cure or prevent any disease, and clinical data referenced herein were generated to support cosmetic-claim substantiation, not any therapeutic indication; results from in-vitro studies and limited-population clinical evaluations may not be predictive of broader real-world results; the Company may not realize anticipated commercial benefits from the U.S. listing; Cellav may not successfully commercialize the products on the timeline expected, or at all; market-size estimates, growth projections and statements regarding investor capital flows are based on third-party sources Pluri has not independently verified; competition; the Company’s ability to obtain additional capital; intellectual property risks; and general market, economic and geopolitical conditions. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
investor.relations@pluri-biotech.com
Haifa, Israel – March 26, 2026 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company’s largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026.
This additional investment follows Mr. Weinstein’s prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further underscores his continued support in Pluri’s strategy, underlying asset base, and long-term value creation opportunity.
“Making an additional investment in Pluri reflects my view that the Company holds a unique combination of highly valuable assets, technology, and capabilities” said Alejandro Weinstein, Chairman of the Board of Pluri. “My goal is to help the Company unlock that value through focused execution, strategic prioritization, and the advancement of the current and future opportunities that can further strengthen Pluri’s momentum.
Yaky Yanay, Chief Executive Officer and President of Pluri, commented: “I believe Alejandro’s investment is a strong vote of confidence in the value of Pluri’s assets, platform, and future opportunities. We share the goal of unlocking this value through focused execution, strategic prioritization, and advancement of the initiatives we believe can create meaningful shareholder value.”
The Securities Purchase Agreement relates to a private placement offering consisting of: 625,000 common shares, par value $0.00001 per share of the Company, and warrants to purchase up to 625,000 common shares of the Company The combined purchase price for each common share and common warrant is $4.00. The warrants are exercisable immediately upon closing of the transaction at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary of the closing of the transaction. The gross proceeds to the Company from this transaction are expected to be approximately $2.5 million. Pluri intends to use the proceeds from the private placement for general working capital and general corporate purposes.
The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Mr. Alejandro Weinstein
Mr. Weinstein, a prominent investor, has built and scaled global companies across healthcare, biotechnology, and wellness, including transforming CFR Pharmaceuticals into a multinational group later acquired by Abbott for $2.9 billion, and founding leading investment platforms such as WM Partners, Olive Tree Ventures, and Vanterra Ventures, which is active in functional food and nutrition innovation. His proven ability to grow companies, execute strategic transactions, and lead value driven organizations makes him a strong candidate to serve as Chairman.
About Pluri Inc:
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions.
The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses the belief that the Company holds a unique combination of highly valuable assets, technology, and capabilities, the belief that the investment is a strong vote of confidence in the value of Pluri’s assets, platform, and future opportunities , the potential of the Company’s ventures, the Company’s focus on sharpening execution, advancing commercialization and building long-term value for its shareholders, and the expected use of proceeds from the private placement and the timing and completion of the private placement. These forward-looking statements and their implications are based on the current expectations only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the ability to fulfill the closing conditions for the private placement, changes in consumer preferences or aesthetics industry trends; the Company or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by the Company or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing; the Company’s ability to satisfy closing conditions, consummate the private placement on the expected terms or timeline, or at all; and the Company’s ability to use the proceeds as anticipated. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Haifa, Israel (February 18, 2026) – Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has granted Pluri Biotech Ltd., a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and activation technology.
The patent, titled “System and Methods for Immune Cells Expansion and Activation in Large Scale” (Patent No. Cn 119301238 b), expands Pluri’s global intellectual property (IP) portfolio, including granted patents in the United States and additional granted patents in Japan, Korea, Australia and Israel. The expanded portfolio supports the Company’s strategy to pursue global collaboration and licensing agreements for immune cell therapy products built on Pluri’s automated, large- scale manufacturing platform.
The patent family covers large-scale production of diverse immune cell types, both unmodified and genetically modified, across multiple therapeutic areas. The platform enables expansion of cell types spanning lymphoid and myeloid lineages, including conventional and unconventional T cells (such as MAIT), Natural Killer (NK) cells, Tumor Infiltrating Lymphocytes (TIL), and Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) engineered variants.
Securing this new patent in China comes at a pivotal moment for the country’s rapidly expanding cell therapy landscape. China has emerged as one of the world’s most dynamic markets for CAR-T and advanced cell therapies, driven by growing clinical adoption, expanding manufacturing infrastructure, and increased investment. Protecting Pluri’s IP in China not only strengthens our global portfolio but strategically positions us to participate and contribute to one of the fastest-growing ecosystems worldwide.
Pluri’s patented 3D platform addresses these industry bottlenecks and is designed to enable mass production through a unique bioreactor system that mimics the human lymph node environment to expand billions of immune cells. We believe that this approach significantly enhances cost-efficiency by reducing the prohibitive expenses typically associated with traditional cell therapy production, a critical requirement for the high-volume Chinese pharmaceutical market. Furthermore, we believe that the platform ensures rigorous quality control through a fully automated, closed-loop process that maintains batch-to-batch consistency and cell integrity at an industrial scale.
A Strategic Bridge for Global Pharma
With patent protection across the U.S., China, Japan, Korea, Australia and Israel, Pluri provides an “IP Bridge” for partners developing therapies on its platform across the world’s primary healthcare markets. We believe that this broad coverage supports a unified framework for international licensing and development, helping global pharma companies operate in China with greater confidence, while enabling Chinese biotech leaders to pursue global expansion. By protecting key manufacturing methods in both CNIPA and U.S. Patent and Trademark Office jurisdictions, Pluri’s cross-continental defensibility can potentially reduce partnering risk and strengthen high-value collaborations where scalability, quality consistency and IP protection are critical to commercial success.
“We believe that securing patent protection in China, one of the most dynamic cell therapy markets globally, validates the novelty and scalability of our technology,” said Yaky Yanay, chief Executive Officer and President of Pluri. “Together with our granted patents in the U.S., Japan, Korea, Australia and Israel, our goal is to offer partners a globally protected manufacturing platform capable of supporting large-scale immune cell production.”
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, aesthetics and offers Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential benefits to the Company from the new patent grant in China, including strengthening of its positioning in China and the support of cross border partnerships, global collaborations and licensing agreements;; the capacity of its 3D platform to address industry bottlenecks and enable mass production of immune cells, including MAIT cells; the potential for cost-efficiency, quality control in the Chinese pharmaceutical market, batch to batch consistency and cell integrity at an industrial scale; the belief that Pluri’s cross-continental defensibility can reduce partnering risk and strengthen high-value collaborations; the novelty and scalability of the Company’s technology;; the company’s ability to pursue collaborations with Chinese and global pharma companies ; the expected growth and investment trends in the Chinese biotech and cell therapy markets; and the potential impact of its technology on global healthcare solutions. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the patent grant may not be realized as anticipated; Pluri may encounter changes in technology or market conditions; the company may face challenges in scaling its technology or securing commercial partnerships; regulatory developments in China or other jurisdictions could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; and intensified competition in the cell therapy and immuno-oncology space. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com Israel Media: Gali Raz at gali.raz@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Haifa, Israel – January 22, 2026 – Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD (“Resbiomed”), a European biotechnology company developing extracellular-matrix- based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri’s contract development and manufacturing division, PluriCDMO™.
In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contract Development and Manufacturing (“CDMO”) services under its PluriCDMO™ business line, entered into an agreement with Resbiomed to apply Pluri’s proprietary placenta-derived processing and bioprocessing capabilities to enhance,
standardize and enable scalable production of placenta-derived biomaterials containing naturally occurring human collagen. The parties have completed the planned first phase of work, focusing on initial process development and feasibility, and are moving forward to the next phase, which is focused on further advancing process definition, reproducibility and manufacturing readiness, subject to mutually agreed scope, timelines and applicable requirements.
Under the program, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to support Resbiomed in establishing protocols for tissue extraction, separation and processing designed to preserve, concentrate and enhance endogenous collagen components and yield high-quality biological materials for diverse regenerative-medicine applications. The collaboration builds on Pluri’s experience in placenta-derived manufacturing and complements Resbiomed’s focus on extracellular-matrix (ECM) based biomaterials.
Human collagen and collagen-rich materials are premium biological inputs due to stringent sourcing and quality requirements. Research-grade recombinant human
collagen is often sold in microgram-to-milligram quantities at premium prices, reflecting the complexity of sourcing and manufacturing. Pluri believes scalable, standardized manufacturing of placenta-derived collagen-rich materials can expand access across regenerative medicine, advanced wound care, medical devices, 3D cell culture and bioprinting, and selected aesthetics.
For Pluri, it views the agreement as underscoring growing demand for PluriCDMO services among companies developing next-generation, cell- and tissue-based technologies, and further strengthens PluriCDMO’s position as a partner for biologics and advanced biomaterials programs requiring reproducibility, scale, and robust manufacturing controls.
“We are pleased to announce the completion of the first phase of our program with Resbiomed,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “Resbiomed has built an impressive focus and expertise in ECM-based biomaterials, and we value the strength of the collaboration. This milestone further demonstrates PluriCDMO’s ability to serve as a trusted development and manufacturing partner, applying our placenta-derived processing know-how and advanced bioprocessing capabilities to help accelerate programs, strengthen manufacturing readiness, and support our partners’ path toward commercialization.”
“The collaboration with Pluri enables us to pair our biomaterials development with an experienced manufacturing partner,” said Alexander Angelov, Chief Executive Officer of Resbiomed. “Completing the first phase marks important progress in our program. We look forward to advancing the next phase as we continue working toward scalable supply and consistent quality for our regenerative-medicine development activities.”
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit pluri-biotech.com or follow Pluri on LinkedIn and X.
Pluri launched its CDMO division in January 2024, leveraging its proprietary knowledge, cutting-edge technology and cell therapy production facility on behalf of clients.
PluriCDMO™ clients gain access to Pluri’s state-of-the-art GMP facilities, and to Pluri’s patented bioreactor system, which enables cell expansion at mass scale via a fully controlled, automated and validated process. For more information visit www.pluri-
biotech.com/cdmo or contact CDMO@Pluri-biotech.com
Resbiomed Technologies OOD is a European biotechnology company developing innovative extracellular-matrix-based materials and biologics for regenerative medicine. The company focuses on biomaterials derived from human tissues, including placenta- based ECM and collagen products intended for a range of therapeutic and medical applications.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Forward- looking statements include, but are not limited to, statements regarding: the program with Resbiomed and the parties’ plans to proceed to subsequent phases; the expected scope, timelines, and outcomes of any such subsequent phases; the expected benefits of the collaboration; the ability to further define, standardize, reproduce, validate, and scale protocols and manufacturing processes for placenta-derived, collagen-rich biomaterials; the potential characteristics, performance, quality, application and breadth of placenta- derived ECM components and biomaterials; PluriCDMO’s ability to support Resbiomed’s development and manufacturing readiness activities; the belief that the agreement underscores growing demand for PluriCDMO services and further strengthens PluriCDMO’s position in the market; and any statements regarding potential commercialization, market adoption, or expanded access to collagen-rich materials across potential use cases. Forward-looking statements are based on the Company’s current expectations, estimates, forecasts, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others: technical and scientific challenges in process development, characterization, and validation; difficulties in achieving reproducibility, quality, consistency, and scalability; variability in biological source materials; risks related to sourcing, eligibility, screening, testing, traceability, handling, and supply continuity of human tissue-derived materials (including placenta-derived materials); manufacturing, scale-up, technology transfer, facility and equipment availability, and GMP compliance risks; changes in applicable laws, regulations, regulatory guidance, or enforcement priorities (including those applicable to human tissue-derived products, biomaterials, and biologics), as well as regulatory review requirements and timelines; dependence on third parties, including suppliers and service providers; the parties’ ability to agree on future scope, budgets, timelines, milestones, and other terms, and the risk that the collaboration is delayed, modified, or terminated; intellectual property and confidentiality risks; competitive developments; market acceptance, adoption, and pricing dynamics; and other risks described in the Company’s filings with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
Haifa, Israel – December 22, 2025 – Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq,
TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for
cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
Under the ongoing collaboration Remedy Cell’s personnel, along with Pluri’s Contract Development and Manufacturing Organization (“CDMO”) division (PluriCDMO™), have successfully completed the full implementation of Remedy Cell’s proprietary manufacturing process into Pluri’s state-of-the-art Good Manufacturing Practice (“GMP”) facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell’s lead candidate. These batches are intended for use in Remedy Cell’s initial Phase 1b clinical trial, representing a major step in its clinical development. This achievement reflects the strong synergy between Remedy Cell’s innovative therapeutic platform and Pluri’s advanced manufacturing facilities.
The completion of these activities demonstrates PluriCDMO™’s potential to serve complex cell- derived and cell-free processes with consistent, scalable, and regulatory-compliant manufacturing solutions. For Remedy Cell, this milestone marks tangible progress on its path toward clinical development and the realization of its mission to bring secretome-based therapies to patients with fibrotic diseases.
Building on this success, Pluri and Remedy Cell are now broadening the scope of their collaboration. PluriCDMO™ will continue to provide additional manufacturing and process- development support as Remedy Cell advances its clinical and pre-commercial programs. The expanded activity underscores the productive partnership between the teams and their shared commitment to advancing next-generation, cell-free biologics that address significant unmet medical needs.
“Working with Pluri has been highly productive,” said Ayelet Dilion-Mashiah, Chief Executive Officer of Remedy Cell. “Pluri’s expertise and professionalism have been invaluable in helping us reach this critical milestone. Completing our clinical-grade manufacturing and preparing for our first clinical trial is a defining achievement for Remedy Cell, and we look forward to continuing this productive partnership.”
“We are proud to continue strengthening our agreement with Remedy Cell, working together to achieve every project milestone — from technology implementation and engineering runs to the successful manufacture of clinical-grade batches for their first human trial,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “Remedy Cell’s scientific approach is highly innovative, and it has been a privilege to contribute to their progress. This success further positions PluriCDMO™ as a trusted partner for companies developing complex, cell-derived therapies.”
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Pluri launched its CDMO division in January 2024, leveraging its proprietary knowledge, cutting- edge technology and cell therapy production facility on behalf of clients. PluriCDMO™ clients gain access to Pluri’s state-of-the-art GMP facilities, and to Pluri’s patented bioreactor system, which enables cell expansion at mass scale via a fully controlled, automated and validated process. For more information visit www.pluri-biotech.com/cdmo or contact CDMO@Pluri- biotech.com
Remedy Cell Ltd., is a clinical stage biopharmaceutical company revolutionising fibrotic disease treatment with cell-derived, cell-free breakthrough therapies. The company’s proprietary Activated Remedy Cell Secretome (ARcS) platform delivers multi-target, pro-regenerative solutions for complex fibrotic conditions. The company’s lead product, RC-0315, a first-in-class activated MSC-derived secretome therapy for of Idiopathic Pulmonary Fibrosi (“IPF”), has shown in definitive preclinical studies the potential to repair lung tissue and restore function. IPF is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a median survival of only 2-5 years post-diagnosis. Despite the considerable impact of these diseases, current therapeutic options remain limited in both efficacy and scope, creating an urgent need for innovative approaches. To learn more, visit www.remedycell.com or follow Remedy Cell on LinkedIn.
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expectation that the clinical-grade batches of Remedy Cell’s lead candidate will be used in Remedy Cell’s initial Phase 1 clinical trial; the belief that the completion of the listed activities reflects PluriCDMO’s proven ability to serve complex cell-derived and cell-free processes with consistent, scalable, and regulatory-compliant manufacturing solutions; Remedy Cell’s ability to progress on its path toward clinical development and the realization of its mission to bring secretome-based therapies to patients with fibrotic diseases; Pluri and Remedy Cell’s ability to broaden the scope of their agreement, including Pluri’s ability to provide additional manufacturing and process- development support, and Remedy Cell’s ability to advance its clinical and pre-commercial programs; and the expectation that Pluri’s and Remedy Cell’s underscore the productive partnership between the teams and their shared commitment to advancing next-generation, cell- free biologics that address significant unmet medical needs. . These forward-looking statements and their implications are based on the current expectations of Pluri’s and Remedy Cell’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com Israel Media: Shachar Yental at shacharye@gitam.co.il
Haifa, Israel – December 9, 2025 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the Company’s largest shareholders, has been appointed Chairman of the Board of Directors. The appointment reflects the Board’s view that Mr. Weinstein brings a decisive, business driven perspective that aligns with Pluri’s objectives of strengthening market positioning and accelerating the recognition and realization of the significant value embedded in the Company’s underlying assets.
“I am honored to take on the role of Chairman and am fully committed to make the strategic changes needed for driving Pluri into its next stage of growth,” said Alejandro Weinstein. “Pluri has a strong platform, promising commercial pathways, and a portfolio of assets that I believe hold significant untapped potential. Together with the management team, I look forward to building on the Company’s solid foundation, advancing key priorities, and further strengthening strategic initiatives that can unlock the substantial value inherent in our underlying assets, and drive long-term value. I also want to thank Mr. Aberman for his long-standing leadership and meaningful contribution to Pluri’s foundation.”
Mr. Weinstein, a prominent investor, has built and scaled global companies across healthcare, biotechnology, and wellness, including transforming CFR Pharmaceuticals into a multinational group later acquired by Abbott for $2.9 billion, and founding leading investment platforms such as WM Partners, Olive Tree Ventures, and Vanterra Ventures, which is active in functional food and nutrition innovation. His proven ability to grow companies, execute strategic transactions, and lead value driven organizations makes him a strong candidate to serve as Chairman.
As part of this leadership evolution, Mr. Zami Aberman, who has served as Pluri’s Chairman for two decades, will transition into the role of Vice Chairman and continue to support the Company’s strategic direction.
“It has been a privilege to serve as Chairman and to help guide Pluri through key stages of its development,” says outgoing Chairman Zami Aberman.
“Alejandro’s increased involvement reflects the strong potential ahead and his approach to value creation. As I transition into the role of Vice Chairman, I look forward to supporting Pluri’s continued progress and ensuring a smooth leadership transition.”
Yaky Yanay, Chief Executive Officer and President of Pluri, commented: “Mr. Weinstein’s increased investment and appointment as Chairman reflect a clear belief in our direction and mark the beginning of a new phase for Pluri. I want to sincerely thank Mr. Aberman for his leadership over the past two decades and for his continued support as Vice Chairman. With Mr. Weinstein now taking the Chairman role, we are focused on sharpening execution, accelerating commercialization, and unlocking the significant value within our platform and ventures for the benefit of our shareholders and strengthening our position for the years ahead.”
In addition to this leadership transition, Pluri has entered into a Securities Purchase Agreement with an entity beneficially owned by Mr. Weinstein. Pursuant to the agreement, the investor will purchase 625,000 Pluri common shares, together with warrants to purchase up to an additional 625,000 common shares in a private placement, at a combined purchase price of $4. The warrants have an exercise price of $4.25 per share, are exercisable immediately and will be exercisable until June 30, 2026. The transaction is expected to generate aggregate gross proceeds of approximately $2.5 million. Pluri intends to use the proceeds from the private placement for general working capital.
The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions.
The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its objectives of strengthening market positioning, sharpening its commercial execution, and accelerating recognition and realization of the value embedded in its underlying assets, that Pluri has real commercial opportunities and a portfolio of assets that are undervalued by the market, that the Company’s ventures represent meaningful strategic potential, Pluri’s focus on sharpening execution, advancing commercialization and building long-term value for its shareholders, and the expected use of proceeds from the private placement. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Haifa, Israel – November 13, 2025 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell‑based solutions through a collaborative network of ventures, today announced that the Company and its subsidiaries have received multiple awards recognizing excellence in innovation, scientific achievement, and industry leadership.
Pluri was named Overall BioAgriculture Company of the Year by the Biotech Breakthrough Awards last week, highlighting its pioneering work of applying cell therapy and derived technologies to agriculture and sustainable food systems. The award underscores Pluri’s progress in developing scalable cell-based solutions that extend biotechnology’s impact beyond human health into new market sectors.
Pluri’s subsidiaries also achieved other significant industry recognition:
In addition, Israel’s Ministry of Labor, Social Affairs and Social Services has selected Pluri as the winner of the 2024 Egalitarian Employment Award in the Large Company category. Pluri’s Chief Executive Officer and President, Yaky Yanay, is expected to accept the award from Nir Barkat, Israel’s Minister of Economy and Industry, at a ceremony next month in Jerusalem. The Company is also expecting to receive a government grant of 40,000 NIS along with the award. Pluri was also recently listed on Dun’s 100 list of Best HighTech Companies to work for in 2025.
These recognitions reinforce Pluri’s position as a biotechnology leader developing patented and validated, high-value technologies with the potential to transform multiple industries. The Company’s proprietary 3D cell expansion platform enables the development and manufacturing of cell-based products at commercial scale, serving as the foundation for partnerships and ventures in regenerative medicine, food and agtech.
“These awards reflect the strength and versatility of Pluri’s platform, as well as the market confidence in our strategy to apply cell-based innovation across multiple industries,” said Mr. Yanay. “We are proud that our subsidiaries are also being recognized for turning breakthrough science into scalable business solutions that address global challenges in agriculture and food security.”
About Pluri Inc.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, aesthetics and offers Contract Development and Manufacturing Organization services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Forward-Looking Statements
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Pluri’s expectation to receive the Israel’s Ministry of Labor, Social Affairs and Social Services award and the government’s grant of 40,000 NIS, and its technologies’ potential to transform multiple industries. . These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.